MbrlCatalogueTitleDetail

Do you wish to reserve the book?
Thymomatous myasthenia gravis: novel association with HLA DQB105:01 and strengthened evidence of high clinical and serological severity
Thymomatous myasthenia gravis: novel association with HLA DQB105:01 and strengthened evidence of high clinical and serological severity
Hey, we have placed the reservation for you!
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Thymomatous myasthenia gravis: novel association with HLA DQB105:01 and strengthened evidence of high clinical and serological severity
Oops! Something went wrong.
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Title added to your shelf!
Title added to your shelf!
View what I already have on My Shelf.
Oops! Something went wrong.
Oops! Something went wrong.
While trying to add the title to your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Thymomatous myasthenia gravis: novel association with HLA DQB105:01 and strengthened evidence of high clinical and serological severity
Thymomatous myasthenia gravis: novel association with HLA DQB105:01 and strengthened evidence of high clinical and serological severity

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
How would you like to get it?
We have requested the book for you! Sorry the robot delivery is not available at the moment
We have requested the book for you!
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Thymomatous myasthenia gravis: novel association with HLA DQB105:01 and strengthened evidence of high clinical and serological severity
Thymomatous myasthenia gravis: novel association with HLA DQB105:01 and strengthened evidence of high clinical and serological severity
Journal Article

Thymomatous myasthenia gravis: novel association with HLA DQB105:01 and strengthened evidence of high clinical and serological severity

2019
Request Book From Autostore and Choose the Collection Method
Overview
BackgroundThe relative prevalence of myasthenia gravis (MG) subtypes is changing, and their differential features and association with HLA class II alleles are not completely understood.MethodsAge at onset, presence/absence of autoantibodies (Ab) and thymoma were retrospectively considered in 230 adult Italian patients. Clinical severity, assessed by MGFA scale, and the highest Ab titer were recorded. Furthermore, we performed low/high resolution typing of HLA-DRB1 and HLA-DQB1 alleles to detect associations of these loci with MG subtypes.ResultsThere were two peaks of incidence: under 41 years of age, with female preponderance, and over 60 years, with higher male prevalence. The former group decreased and the latter increased significantly when comparing onset period 2008–2015 to 2000–2007. Thymomatous (TMG) patients showed a higher prevalence of severe phenotype and significantly higher anti-AChR Ab titer than non-thymomatous (NTMG) patients. Among the latter, those with onset after 60 years of age (LO-NTMG) displayed significantly higher Ab titers but lower MGFA grade compared to early-onset patients (< 41 years; EO-NTMG). Significant associations were found between HLA DQB1*05:01 and TMG patients and between DQB1*05:02 and DRB1*16 alleles and LO-NTMG with anti-AChR Ab.ConclusionsTwo distinct cutoffs (< 41 and > 60 years) conveniently define EO-NTMG and LO-NTMG, with different characteristics. LO-NTMG is the most frequent disease subtype, with an increasing incidence. TMG patients reach higher clinical severity and higher antibody titers than NTMG patients. Moreover, TMG and LO-NTMG with anti-AChR Ab differ in their HLA-DQ association, providing further evidence that these two forms may have different etiologic mechanisms.